’Sympathy goes out to...’: AstraZeneca reaffirms safety of Covishield, Vaxzevria vaccines amid blood clot concerns

AstraZeneca reaffirms commitment to patient safety and safety profile of vaccines amid concerns over rare side effects of COVID-19 vaccine. AstraZeneca had acknowledged that its Covid vaccines, Covishield and Vaxzevria, ‘can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome (TTS)’.

Livemint
Updated1 May 2024
 AstraZeneca recently acknowledged that its Covid vaccines, Covishield and Vaxzevria, ‘can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome (TTS)’.
AstraZeneca recently acknowledged that its Covid vaccines, Covishield and Vaxzevria, ‘can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome (TTS)’.(Reuters)

Amid recent concerns over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant has reaffirmed its dedication to patient safety, while underscoring its overall safety profile.

An AstraZeneca spokesperson said, "We extend our sympathy to anyone who has lost loved ones or experienced health issues. Patient safety remains our top priority, and regulatory authorities have stringent standards to ensure the safe use of all medicines, including vaccines."

The move follows AstraZeneca's recent acknowledgment that its Covid vaccines, Covishield and Vaxzevria, ‘can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome (TTS)’.

However, the pharmaceutical company asserts that extensive clinical trial data and real-world evidence consistently demonstrate the vaccine's safety and efficacy. Regulatory agencies worldwide maintain that the benefits of vaccination outweigh the risks of such extremely rare side effects.

In 2023, the World Health Organization (WHO) reported that Thrombosis Thrombocytopenia Syndrome (TTS) emerged as a new adverse event following immunization with COVID-19 vaccines based on non-replicating adenovirus vectors.

WHO stated that TTS is a serious and life-threatening adverse event. It issued interim emergency guidance to raise awareness about TTS in the context of COVID-19 vaccination, and to assist healthcare providers in assessing and managing potential TTS cases.

AstraZeneca had partnered with the Serum Institute of India (SII), the world's largest vaccine manufacturer, to supply the vaccine to the Indian Government. The Serum Institute of India produced a COVID-19 vaccine named Covishield.

Thrombosis Thrombocytopenia Syndrome (TTS)

Thrombosis Thrombocytopenia Syndrome (TTS) is a rare but serious condition characterized by blood clot formation (thrombosis) and low levels of platelets in the blood (thrombocytopenia). It can be a rare side effect following vaccination, particularly with adenovirus vector-based COVID-19 vaccines. Symptoms may include severe headache, abdominal pain, leg swelling, and shortness of breath.

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.MoreLess
HomeNews’Sympathy goes out to...’: AstraZeneca reaffirms safety of Covishield, Vaxzevria vaccines amid blood clot concerns

Most Active Stocks

Bharat Electronics

309.55
10:29 AM | 14 JUN 2024
8.6 (2.86%)

Indian Oil Corporation

170.30
10:25 AM | 14 JUN 2024
1.2 (0.71%)

HDFC Bank

1,597.45
10:28 AM | 14 JUN 2024
16.55 (1.05%)

State Bank Of India

840.20
10:29 AM | 14 JUN 2024
-3.7 (-0.44%)
More Active Stocks

Market Snapshot

  • Top Gainers
  • Top Losers
  • 52 Week High

JK Paper

490.70
10:25 AM | 14 JUN 2024
44.35 (9.94%)

KRBL

310.05
10:22 AM | 14 JUN 2024
23.05 (8.03%)

Poly Medicure

2,003.00
09:59 AM | 14 JUN 2024
142.9 (7.68%)

KEC International

935.20
10:25 AM | 14 JUN 2024
66.25 (7.62%)
More from Top Gainers

Recommended For You

    More Recommendations

    Gold Prices

    • 24K
    • 22K
    Bangalore
    73,229.00-212.00
    Chennai
    73,658.00288.00
    Delhi
    73,444.00289.00
    Kolkata
    73,229.00432.00

    Fuel Price

    • Petrol
    • Diesel
    Bangalore
    99.84/L0.00
    Chennai
    100.75/L0.00
    Kolkata
    103.94/L0.00
    New Delhi
    94.72/L0.00
    OPEN IN APP
    HomeMarketsPremiumInstant LoanGet App